Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989 Jan-Feb:297:148-57.

Muscarinic supersensitivity and subsensitivity induced by chronic treatment with atropine and diisopropylfluorophosphate in rat submaxillary glands

Y Ukai  1 , N Taniguchi, T Ishima, K Kimura
Affiliations
  • PMID: 2730233

Muscarinic supersensitivity and subsensitivity induced by chronic treatment with atropine and diisopropylfluorophosphate in rat submaxillary glands

Y Ukai et al. Arch Int Pharmacodyn Ther. 1989 Jan-Feb.

Abstract

Rats were given atropine for 2 weeks and a cholinesterase inhibitor, diisopropylfluorophosphate (DFP) for 4 weeks. The secretory response of the submaxillary glands to pilocarpine and the muscarinic receptor binding to [3H]quinuclidinyl benzylate (QNB) and [3H]pirenzepine (PZ) in the submaxillary glands were investigated. Experiments were performed 48 and 24 hr after the last administration of atropine and DFP, respectively. Chronic atropine treatment enhanced the secretory response and increased the number of binding sites for [3H]QNB and [3H]PZ. The increase in number of binding sites for the 2 radioligands was almost the same. Chronic DFP treatment caused a marked decrease in the secretory response to pilocarpine, without affecting [3H]PZ and [3H]QNB binding. These results suggest that the cholinergic muscarinic M1 receptors may contribute to the development of the supersensitivity of the salivary glands caused by atropine, but not to the development of subsensitivity caused by DFP.

PubMed Disclaimer